Shopping Cart 0
Cart Subtotal
USD 0

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2)-Pipeline Review, H2 2017

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 3500

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 7000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 10500
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2)-Pipeline Review, H2 2017

Summary

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2)-Nuclear factor (erythroid-derived 2)-like 2 or Nrf2 is a transcription factor encoded by the NFE2L2 gene. It binds to antioxidant response elements in the promoter regions of target genes. It is important for the coordinated up-regulation of genes in response to oxidative stress. It is involved in the transcriptional activation of genes of the beta-globin cluster by mediating enhancer activity of hypersensitive site 2 of the beta-globin locus control region.

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) pipeline Target constitutes close to 35 molecules. Out of which approximately 25 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 4, 2, 3, 15 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 7 and 3 molecules, respectively. Report covers products from therapy areas Central Nervous System, Immunology, Oncology, Metabolic Disorders, Cardiovascular, Respiratory, Ophthalmology, Gastrointestinal, Toxicology, Genetic Disorders, Genito Urinary System And Sex Hormones, Infectious Disease and Musculoskeletal Disorders which include indications Inflammation, Multiple Sclerosis, Chronic Obstructive Pulmonary Disease (COPD), Diabetic Nephropathy, Psoriasis, Type 2 Diabetes, Amyotrophic Lateral Sclerosis, Cardiomyopathy, Diabetic Complications, Friedreich Ataxia, Parkinson's Disease, Pulmonary Arterial Hypertension, Systemic Sclerosis (Scleroderma), Type 1 Diabetes (Juvenile Diabetes), Age Related Macular Degeneration, AIDS Associated Dementia, Alport Syndrome, Alzheimer's Disease, Aspiration Pneumonitis, Asthma, Atherosclerosis, Autism, Brain Ischemia, Breast Cancer, Cardiovascular Disease, Cerebral Vasospasm, Chagas Disease (American Trypanosomiasis), Chronic Kidney Disease (Chronic Renal Failure), Encephalomyelitis, Focal Segmental Glomerulosclerosis (FSGS), Huntington Disease, Idiopathic Pulmonary Fibrosis, Idiopathic Pulmonary Hypertension, Ischemia Reperfusion Injury, Ischemic Stroke, Medulloblastoma, Metastatic Breast Cancer, Metastatic Melanoma, Mitochondrial Diseases, Nephropathy, Neuro Muscular Disorders, Neuroblastoma, Neurodegenerative Diseases, Non Alcoholic Fatty Liver Disease (NAFLD), Non-Hodgkin Lymphoma, Non-Small Cell Lung Cancer, Osteoarthritis, Osteoporosis, Ovarian Cancer, Plaque Psoriasis (Psoriasis Vulgaris), Polycystic Kidney Disease, Post-Myocardial Infarction, Primary Progressive Multiple Sclerosis (PPMS), Prostate Cancer, Pulmonary Hypertension, Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), Radiodermatitis, Relapsing Remitting Multiple Sclerosis (RRMS), Retinal Degeneration, Retinopathy, Subarachnoid Hemorrhage and Ulcerative Colitis.

The latest report Nuclear Factor Erythroid 2 Related Factor 2-Pipeline Review, H2 2017, outlays comprehensive information on the Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2)

The report reviews Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics and enlists all their major and minor projects

The report assesses Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it'smost promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

READ MORE

Table Of Content

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2)-Overview

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2)-Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2)-Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2)-Companies Involved in Therapeutics Development

Arbor Pharmaceuticals LLC

Bayer AG

BioApex sro

Biogen Inc

C4X Discovery Holdings PLC

Catabasis Pharmaceuticals Inc

Daiichi Sankyo Co Ltd

Evgen Pharma Plc

Ixchel Pharma LLC

Jiangsu Hengrui Medicine Co Ltd

Mochida Pharmaceutical Co Ltd

Reata Pharmaceuticals Inc

Rigel Pharmaceuticals Inc

vTv Therapeutics Inc

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2)-Drug Profiles

BA-1521-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bardoxolone methyl-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CAT-4001-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DH-404-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dimethyl fumarate DR-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IXC-103-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LGM-2605-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LH-503-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LH-526-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MG-132-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MIND-4-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

monosodium luminol-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nifurtimox-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

omaveloxolone-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

R-970-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RS-9-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RTI-79-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SFX-01-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SFX-02-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SFX-03-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Activate NF-E2 Related Factor 2 for Central Nervous System, Metabolic Disorders, Cardiovascular and Ophthalmology-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Activate Nrf2 for Inflammation-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Activate Nrf2 for Inflammation-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Target NRF2 and BACH1 for Parkinson'sDisease-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules 2 to Activate Nrf2 for Oncology and Inflammation-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Activate NRF-2 for COPD-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Activate Nrf2 for Oncology and Inflammation-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit GSK3B and Activate Nrf2 for Alzheimer's Disease-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SUL-121-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TBE-31-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tepilamide fumarate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TFM-735-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VCB-101-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VCB-102-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VEDA-1209-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2)-Dormant Products

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2)-Discontinued Products

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2)-Product Development Milestones

Featured News & Press Releases

Dec 11, 2017: Hardman Research: Funded to the end of Phase II trials

Dec 11, 2017: Reata Pharmaceuticals Presents Interim Phase 1b Data for Omaveloxolone in the Treatment of Unresectable or Metastatic Melanoma

Dec 08, 2017: Novel Compound Restores Immune Response In Patients With Melanoma

Nov 06, 2017: Kyowa Hakko Kirin Presented Results of Phase II Study of Bardoxolone Methyl in Japan at the ASN Kidney Week

Nov 06, 2017: Reata Provides Update on Bardoxolone Methyl from the American Society of Nephrology Kidney Week Meeting

Nov 03, 2017: Reata Announces Primary Results from the Phase 2 CARDINAL Study of Bardoxolone in Alport Syndrome at the American Society of Nephrology Kidney Week 2017 Annual Meeting

Oct 23, 2017: Reata Announces First Patient Enrolled in Part 2 of MOXIe Study of Omaveloxolone for the Treatment of Friedreich'sAtaxia

Oct 20, 2017: Reata Announces Late-Breaking Presentation of Primary Results From Phase 2 CARDINAL Study at the American Society of Nephrology Kidney Week 2017 Annual Meeting

Oct 04, 2017: Evgen Pharma: First European Patent Grant

Sep 13, 2017: Reata Pharmaceuticals, Inc. Receives Orphan Drug Designation for Omaveloxolone for the Treatment of Malignant Melanoma

Aug 14, 2017: FDA Confirms That Use of mFARS as Primary Endpoint in Part 2 of the MOXIe Trial Can Support Approval of Omaveloxolone in Friedreich'sAtaxia

Aug 07, 2017: Reata Announces First Patient Enrolled in Phase 3 CARDINAL Trial of Bardoxolone Methyl in the Treatment of Chronic Kidney Disease Due to Alport Syndrome

Aug 02, 2017: Evgen Pharma: SFX-01 data published in Peer Reviewed Journal

Aug 01, 2017: Department Of Defense Report Shows Bach Pharma Drug GVT Reverses Brain Dysfunction

Jul 24, 2017: Reata'sBardoxolone Methyl Demonstrated Improved Kidney Function in Patients With Alport Syndrome in Ongoing Phase 2 Portion of Phase 2/3 Cardinal Study

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Top 10 Indications, H2 2017

Number of Products by Mechanism of Actions, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017


List Of Table

List of Tables

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Indications, H2 2017

Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Indications, H2 2017 (Contd..2), H2 2017

Number of Products under Development by Indications, H2 2017 (Contd..3), H2 2017

Number of Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Number of Products under Investigation by Universities/Institutes, H2 2017

Products under Investigation by Universities/Institutes, H2 2017

Products under Investigation by Universities/Institutes, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Pipeline by Arbor Pharmaceuticals LLC, H2 2017

Pipeline by Bayer AG, H2 2017

Pipeline by BioApex sro, H2 2017

Pipeline by Biogen Inc, H2 2017

Pipeline by C4X Discovery Holdings PLC, H2 2017

Pipeline by Catabasis Pharmaceuticals Inc, H2 2017

Pipeline by Daiichi Sankyo Co Ltd, H2 2017

Pipeline by Evgen Pharma Plc, H2 2017

Pipeline by Ixchel Pharma LLC, H2 2017

Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2017

Pipeline by Mochida Pharmaceutical Co Ltd, H2 2017

Pipeline by Reata Pharmaceuticals Inc, H2 2017

Pipeline by Rigel Pharmaceuticals Inc, H2 2017

Pipeline by vTv Therapeutics Inc, H2 2017

Dormant Products, H2 2017

Dormant Products, H2 2017 (Contd..1), H2 2017

Dormant Products, H2 2017 (Contd..2), H2 2017

Discontinued Products, H2 2017

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies


Companies

Arbor Pharmaceuticals LLC

Bayer AG

BioApex sro

Biogen Inc

C4X Discovery Holdings PLC

Catabasis Pharmaceuticals Inc

Daiichi Sankyo Co Ltd

Evgen Pharma Plc

Ixchel Pharma LLC

Jiangsu Hengrui Medicine Co Ltd

Mochida Pharmaceutical Co Ltd

Reata Pharmaceuticals Inc

Rigel Pharmaceuticals Inc

vTv Therapeutics Inc